nanotech investing Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome
nanotech investing Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome
nanotech investing Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
nanotech investing Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
nanotech investing Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
nanotech investing Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
nanotech investing Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease
nanotech investing New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference
nanotech investing Longeveron Granted Small or Medium-sized Enterprise Status by the European Medicines Agency
Pinnacle Prepares Plans for Drilling and Field Work to Follow Up on Polymetallic Discoveries at El Potrero
